Skip to content

Author

Guillaume Cayla

We have 5 of 48 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

Predictors of cardiac rehabilitation completion after acute myocardial infarction in young women: the French WAMIF Registry

Abstract Aims Cardiac rehabilitation (CR) is a cornerstone of secondary prevention after acute myocardial infarction (AMI), yet its implementation remains suboptimal, particularly among women. Young women represent an understudied subgroup with distinct presentations and psychosocial vulnerabilities that may influence...

P. Piriou, T. Angoulvant, C. Bouleti et al. · 0 citations
Open access Oct 2026

Percutaneous coronary intervention using sirolimus-eluting balloons in patients at high bleeding risk: the SELUTION DeNovo HBR substudy.

BACKGROUND Drug-eluting stents (DES) are the current mainstay of percutaneous coronary intervention (PCI) in high bleeding risk (HBR) patients. However, drug-coated balloons may be an alternative that reduces reliance on prolonged courses of antiplatelet therapy. AIMS The SELUTION DeNovo trial randomised 3,323 PCI ca...

Tuomas T. Rissanen, Simon Eccleshall, Florian Krackhardt et al. · 0 citations
Review Aug 2026

Discontinuation of β-blockers in stable patients with previous myocardial infarction, preserved left ventricular ejection fraction, and no heart failure: a pooled analysis of individual patient data.

In stable patients with previous myocardial infarction, left ventricular ejection fraction ≥40%, no heart failure, and no other indication for β-blocker therapy, discontinuation met the non-inferiority criteria for the primary and key secondary endpoints.

J. Silvain, Ki H. Choi, Victorien Monguillon et al. · 1 citation
Open access Aug 2026

LDL Cholesterol Lowering With Evolocumab Before Percutaneous Coronary Intervention for Acute Myocardial Infarction: The AMUNDSEN Randomized Clinical Trial.

In patients with acute MI undergoing PCI, first-line evolocumab combined with high-intensity lipid-lowering therapy produced rapid and sustained LDL-C reduction, with more than 80% of patients reaching the guideline-recommended target at 1 year.

G. Montalescot, E. Ferrari, G. Souteyrand et al. · 3 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.